The future of treatment of CLL is not clear. I think that the landscape has been revolutionized by the BTK inhibitors and the BCL-2 inhibitors, in particular, venetoclax. More BCL-2 inhibitors are coming up, so we will see if we can have a safer, more manageable drug to be used. At the moment, the frontier seems to be the combination of drugs, two or three drugs together in a fixed duration fashion...
The future of treatment of CLL is not clear. I think that the landscape has been revolutionized by the BTK inhibitors and the BCL-2 inhibitors, in particular, venetoclax. More BCL-2 inhibitors are coming up, so we will see if we can have a safer, more manageable drug to be used. At the moment, the frontier seems to be the combination of drugs, two or three drugs together in a fixed duration fashion.
We still don’t know if this is better than a sequential therapy of single monotherapies or a combination of one therapy with monoclonal antibodies followed by another monotherapy. So that remains to be established and we need studies to see if this is important. Of course, the future is also open for CAR T-cells that here at ASH have been shown even in early lines to be very effective in diffuse large B-cell lymphoma and in other lymphomas. In CLL, we are a little behind. The efficacy still remains low. There will probably be an approval of the first CAR-T in CLL in the next year, but still a lot of work has to be done until it really becomes available for everyone.